Předmět: |
|
Zdroj: |
Cancer Weekly; 12/12/2023, p1033-1033, 1p |
Abstrakt: |
Researchers from Cold Spring Harbor Laboratory have made new findings in liver cancer, specifically in relation to CRISPR/Cas9 technology. The researchers discovered that using CRISPR/Cas9 to target a specific gene called Ctnnb1 resulted in exon skipping and the generation of gain-of-function isoforms in vivo. This led to the formation of liver tumors in mice. The researchers also identified similar exon-skipping events in patients with hepatocellular carcinoma. These findings contribute to our understanding of beta-catenin-related tumorigenesis and demonstrate the potential of CRISPR/Cas9 for studying gain-of-function mutations in cancer. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|